As the parent company, the Mitsubishi Chemical Group made the business decision to cease support for the operations of its partner, Medicago. We will of course be closely following the next steps in this process in order to preserve Medicago's talent, research laboratories and production facilities as much as possible.
I'll also note more broadly that the government has invested over $2.1 billion in a biomanufacturing life science strategy to support numerous businesses across Canada in all stages of vaccine and therapy production, including an agreement with Moderna to establish a manufacturing facility in Quebec.